TAKING A BOLD & INNOVATIVE APPROACH TO TRANSFORMING PATIENTS’ LIVES
In addition to our gene therapy portfolio targeting serious rare neuromuscular diseases, we are leveraging Astellas’ global resources, industry leadership in immune biology, and deep scientific expertise to expand our reach and deliver valuable new genetic medicines to patients around the world.
We see the patient community as our partners, collaborators, and teachers. We believe that their perspectives should be integrated throughout the drug development process from initiation of a clinical program to its completion and beyond.
The science of making AAV-based genetic medicines is complex. Our robust research laboratory and state-of-the-art vector manufacturing facility puts us at the forefront of developing innovative products. Our bold approach is driven by our commitment to bringing transformative treatments to patients living with serious rare neuromuscular diseases as rapidly as possible.
Media & Social Updates
October 5, 2019
Audentes Therapeutics Presents New Positive Data from ASPIRO, the Clinical Trial Evaluating AT132 in Patients with X-Linked Myotubular Myopathy (XLMTM), at the 24th International Annual Congress of the World Muscle Society
Audentes is different – we take time to understand our patient communities and weave that knowledge with our scientific insights to develop transformative therapies. Follow us on Facebook to share with us, stay updated and learn more.
What bold things can you expect from us next? Keep track of company announcements, by following us on Twitter!